Current Research Trials

Georgia Pollens Clinical Research Centers, Inc.
105 Spanish Court, Albany, Georgia 31707
Telephone: 229-883-8909 Fax: 229-317-0609

AstraZeneca ANDHI—Protocol D3250C00045 ***Evaluating the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment*** Ages 18 and older on a moderate to high dose of ICS with an additional controller therapy for 12 months (stable for 3 months) and 2 asthma exacerbations within the previous 12 month period; ACQ score of ≥ 1.5 at visit 1; screening pre-bronchodilator of < 80% and a serum eosinophil count of >300 cells/uL at visit 1 or 2. **MUST remain at site for 2 hours post injection.** (Length of trial = 24 weeks after randomization.)
Compensation to subjects: $60 after each completed visit for a total of 11 visits

BAXALTA 161406—A Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA: Ages ≥16 years and older who have been prescribed or started on Hyqvia. Visit swill be coordinated with office visits and/or every 3 months.
(Length of trial = 52 weeks, with the potential to continue for an additional year depending on blood results)
Compensation to participants: $25 after each completed visit.

Genentech GB39242--Protocol Title: GB39242: ASSESSING THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA Ages 18--75 years; (BMI) of 18−35 kg/m2 and weight ≥ 40 kg at screening; On ICS therapy at a total daily dose ≥ 500 µg of fluticasone propionate or equivalent plus at least one additional allowed controller medication, for ≥ 3 months prior to screening, with no changes within 4 weeks prior to screening; **Documented history of at least one asthma exacerbation within 12 months prior to screening while on daily ICS maintenance therapy (same dose as at screening**; Documented physician-diagnosed asthma for at least 12 months prior to screening Morning pre-bronchodilator FEV1 of 40%−80% of predicted at the screening and run-in (Week 0) visits. **This sponsor is having a VERY difficult time enrolling globally.**
(Length of trial = 70 weeks, not including a 3 week run-in period)
Compensation to participants: $75 after each completed visit or for 18 visits.

LeoPharma LP0162-1325 ECZTRA-- Tralokinumab monotherapy for **moderate-to-severe atopic dermatitis in subjects 18 years and older.** Diagnosis of atopic dermatitis for ≥ 1 year. The trial is as follows: two screening visits with 20 weeks of double-blind Tralokinumab; followed by 34 weeks of open-label Tralokinumab treatment and a 16-week short-term extension period of open-label Tralokinumab and a FINAL follow-up visit. MULTIPLE skin scoring assessments at each visit preferably by the initial clinician.
Compensation to participants: $75 after each completed visit, every 2 weeks ("potential" to have 39 total visits).